Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.34 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2779759 | 0.84 | NFE2L2 (0.37) | TAAR1NFE2L2CYP2A6GAAATM | |
| SCHEMBL30583474 | 0.84 | NFE2L2 (0.37) | TAAR1NFE2L2CYP2A6GAAATM | |
| SCHEMBL29618975 | 0.79 | PSEN1 (0.40) | NFE2L2CYP2A6ALDH1A1SLC6A4 | |
| SCHEMBL1020440 | 0.79 | PSEN1 (0.40) | NFE2L2CYP2A6ALDH1A1SLC6A4 | |
| Water SCHEMBL17670054 | 0.79 | TAAR1 (0.50) | TAAR1HTTGAAATMALDH1A1 | |
| SCHEMBL1019451 | 0.79 | TAAR1 (0.50) | TAAR1HTTGAAATMALDH1A1 | |
| SCHEMBL836823 | 0.78 | CYP2A6 (0.50) | HTTCYP2A6ALDH1A1HTR2CSLC6A4 | |
| SCHEMBL268462 | 0.77 | TAAR1 (0.42) | TAAR1NFE2L2HTTCYP2A6MAPK1 | |
| SCHEMBL24786214 | 0.76 | AR (0.41) | CYP2A6GAAALDH1A1 | |
| SCHEMBL9543269 | 0.76 | ESR2 (0.45) | MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4822903-A | Fluorinated silica catalyst and preparation of aromatic/aliphatic nitriles in the presence thereof | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1989-04-18 | — | — | US | claimed |
| US-4438042-A | FROM AMIDES, FLUORINATE SILCEOUS CATALYSTS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-03-20 | — | — | US | claimed |
| US-4436669-A | CYANATION, DECARBONYLATION, ACID CATALYSTS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-03-13 | — | — | US | claimed |
| EP-2791137-B1 | PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION PROCESS THEREFOR AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2019-01-23 | — | — | EP | disclosed |
| EP-2794565-B1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-2366699-B1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2366699-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| US-4822903-A | Fluorinated silica catalyst and preparation of aromatic/aliphatic nitriles in the presence thereof | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1989-04-18 | — | — | US | disclosed |
| US-4504595-A | Fluorinated silica catalyst and preparation of aromatic/aliphatic nitriles in the presence thereof | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1985-03-12 | — | — | US | disclosed |
| US-4438042-A | FROM AMIDES, FLUORINATE SILCEOUS CATALYSTS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-03-20 | — | — | US | disclosed |
| US-4436669-A | CYANATION, DECARBONYLATION, ACID CATALYSTS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | TAAR1 117/4885NFE2L2 439/4885HTT 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.